JAN 31, 2018 11:28 AM PST

Getting to the Details of how Antipsychotic Drugs Work

WRITTEN BY: Carmen Leitch

Around 1.6 percent of adults take antipsychotic medication, according to one study, but their mode of efficacy is not well understood. Individuals with conditions like bipolar disorder, schizophrenia, or who are on the autism spectrum may benefit from these drugs, but the medications can also cause serious side effects. Now, researchers at UC San Francisco and the UNC School of Medicine have revealed the crystal structure of the dopamine 2 receptor (DRD2) in high resolution as it is bound to risperidone, an antipsychotic agent. This work, reported in Nature, could go a long way toward aiding drug developers and scientists that are trying to activate DRD2 specifically. That could limit some of the many side effects, which include digestive problems, dizziness, anxiety, agitation and weight gain.

Widely-prescribed antipsychotic drug risperidone (purple) is shown interacting with its primary human brain target, the D2 dopamine receptor (green). Discovery of this molecular structure holds promise for rational design of more selective drugs, say researchers. / Credit: Roth Lab, UNC

“If we want to create better medications, the first step is to see what the D2 receptor looks like in high-resolution detail when it’s bound tightly to a drug,” said senior author Bryan L. Roth, MD, PhD, the Michael Hooker Distinguished Professor of Protein Therapeutics and Translational Proteomics at the UNC School of Medicine. “We now have the structure, and we’re exploring it to find new compounds we hope can help the millions of people in need of better treatments.”

Around a third of available drugs activate molecules called G-protein coupled receptors; located on the surfaces of cells, they send signals that exert therapeutic effects. However, a lack of understanding of the intricate differences separating the various kinds of receptors means that the drugs can affect a wide swath, rather than a specific group of them. Instead of targeting only DRD2, they might also interact with serotonin, histamine, alpha-adrenergic, or other dopamine receptors. Those unintended interactions can cause severe side effects.

Risperidone is a drug commonly used by patients with schizophrenia, bipolar, and autism spectrum disorders. It is a so-called atypical antipsychotic approved for use in kids. Now scientists have determined the high-resolution structure of the drug as it is attached to DRD2.

“With this high-resolution structure in hand, we anticipate the discovery of compounds that interact with DRD2 in specific ways important for greater therapeutic actions and fewer side-effects,” Roth said.

Confirmed by the computational work of UCSF researchers Brian Shoichet, Ph.D., and Anat Levit, Ph.D., risperidone had an unpredictable mode of binding. The receptor has a previously unknown pocket; Roth and colleagues suggested it might be a good target for more selective medications.

"For the first time, we can understand precisely how atypical antipsychotic drugs bind to their primary molecular target in the human brain," explained Dr. Laurie Nadler, chief of the neuropharmacology program at the National Institute of Mental Health (NIMH), study co-funder with the National Institute of General Medical Sciences and the National Cancer Institute. "This discovery opens the way for the rational design of a new generation of antipsychotic drugs, hopefully with more desirable effects and fewer side effects."

“Before coming to UNC, I was a psychiatrist specializing in treating schizophrenia. On a daily basis, it was clear to me that medications were only modestly effective for large numbers of patients. Our lack of knowledge into how antipsychotic drugs bind to their receptors has held back progress towards creating more effective medications,” added Roth. Solving the high-resolution crystal structure of DRD2 bound to the commonly prescribed antipsychotic drug risperidone is the first step towards the creation of safer and more effective medications for schizophrenia and related disorders.”

In the video, Shoichet briefly discusses how structural data can improve biology.


Sources: AAAS/Eurekalert!, NIMH, UNC, Nature

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
DEC 08, 2019
Genetics & Genomics
DEC 08, 2019
Finding a Way to Treat Dangerous Protein Aggregates
The scientists are hopeful that this work will lead to new therapeutics for neurodegenerative disease....
DEC 09, 2019
Microbiology
DEC 09, 2019
A Single-Celled Organism That Seems to Make Choices
A protist has been captured on video 'changing its mind.'...
DEC 15, 2019
Cell & Molecular Biology
DEC 15, 2019
Using a Bacterial Syringe to Deliver Proteins to Cells
Researchers want to use a pathogen's strategy for therapeutic purposes....
DEC 20, 2019
Genetics & Genomics
DEC 20, 2019
Can We Cure Down's Syndrome with Gene Therapy?
Down’s Syndrome (DS) is a genetic disorder brought on by the presence of all of part of a third copy of chromosome 21. Linked to delays in physical g...
JAN 27, 2020
Cell & Molecular Biology
JAN 27, 2020
The 3D Ultrastructure of a Cell is Revealed
Seeing what's going on inside of cells presents many challenges that advances in microscopy have tried to address....
FEB 13, 2020
Cell & Molecular Biology
FEB 13, 2020
Study of Early-Onset Parkinson's Reveals Potential Therapeutic
Around 500,000 Americans are diagnosed with Parkinson's disease every year, and the rate of the disease is rising....
Loading Comments...